P011 Incidence of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) in Norway 1993–2006

W. Marieke Schoonen; Bjarte Aagnes; Freddie Ian Bray; Sylvain Hansen; J. Fryzek; Elisabete Weiderpass

doi:10.1016/s0145-2126(09)70091-8

Article2011

Expression and Function of the P-Glycoprotein (P-gp) In Myelodysplastic Syndromes (MDS) Treated with Azacytidine (AZA)

Marie Sébert, Élodie Lainey, Pascale Lepelley, Sylvain Thépot, Maximilien Tailler, Claude Gardin, Guido Guido Kroemer, Simone Boehrer, Lionel Adès, Pierre Fenaux

Article2022

MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results

David A. Sallman, Monzr M. Al Malki, Adam Asch, Eunice S. Wang, Joseph G. Jurcic, Terrence Bradley, Ian W. Flinn, Daniel A. Pollyea, Suman Kambhampati, Tiffany Tanaka, Joshua F. Zeidner, Guillermo Garcia‐Manero, Deepa Jeyakumar, Lin Gu, Anderson Tan, Mark P. Chao, Carol O’Hear, Indu Lal, Paresh Vyas, Naval Daver

Article2022

Poster: MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results

David A. Sallman, Monzr M. Al Malki, Adam Asch, Eunice S. Wang, Joseph G. Jurcic, Terrence Bradley, Ian W. Flinn, Daniel A. Pollyea, Suman Kambhampati, Tiffany Tanaka, Joshua F. Zeidner, Guillermo Garcia‐Manero, Deepa Jeyakumar, Lin Gu, Anderson Tan, Mark P. Chao, Carol O’Hear, Indu Lal, Paresh Vyas, Naval Daver

Article2022

Oral Abstract: MDS-445 Magrolimab In Combination with Azacitidine for Patients with Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results

David A. Sallman, Monzr M. Al Malki, Adam Asch, Eunice S. Wang, Joseph G. Jurcic, Terrence Bradley, Ian W. Flinn, Daniel A. Pollyea, Suman Kambhampati, Tiffany Tanaka, Joshua F. Zeidner, Guillermo Garcia‐Manero, Deepa Jeyakumar, Lin Gu, Anderson Tan, Mark P. Chao, Carol O’Hear, Indu Lal, Paresh Vyas, Naval Daver

Article2014

A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure

Sylvain Thépot, Simone Boehrer, Valérie Seegers, Thomas Prébet, Odile Beyne‐Rauzy, Eric Wattel, Jacques Delaunay, Emmanuel Raffoux, Mathilde Hunault, Éric Jourdan, Fatiha Chermat, Marie Sébert, Guido Guido Kroemer, Pierre Fenaux, Lionel Adès

P011 Incidence of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) in Norway 1993–2006

Discussion(0)

Related publications

Expression and Function of the P-Glycoprotein (P-gp) In Myelodysplastic Syndromes (MDS) Treated with Azacytidine (AZA)

MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results

Poster: MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results

Oral Abstract: MDS-445 Magrolimab In Combination with Azacitidine for Patients with Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results

A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure